{"entity":{"id":"mermaid-2","kind":"trial","name":"MERMAID-2","aka":[],"tldr":"A lung cancer trial that planned to start durvalumab the moment a surveillance blood test found tumour DNA, before any scan showed relapse; the registry lists it as complete with 30 participants.","summary":"MERMAID-2 was AstraZeneca's phase 3, double-blind trial of durvalumab against placebo for people with stage II to III non-small-cell lung cancer whose ctDNA became detectable during surveillance after curative treatment, the 'treat at molecular relapse' design. The registry records a start on 30 November 2020, a status of completed with 30 participants, primary completion on 31 May 2023 and study completion on 15 January 2024. Its small size is the reason the roadmap describes ctDNA-triggered escalation as unproven outside bladder cancer.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04642469","url":"https://clinicaltrials.gov/study/NCT04642469"}],"tags":["ctdna-roadmap"],"related":["mermaid-1","ctdna-tests"],"cancers":["nsclc"],"sections":[],"technologies":["mrd-testing","liquid-biopsy","continuous-ctdna-monitoring"],"targets":[],"drugs":["durvalumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":["mrd","ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04642469","phase":"3","setting":"Stage II to III non-small-cell lung cancer after surgery and curative treatment: durvalumab against placebo started when ctDNA becomes detectable during surveillance","sponsor":"AstraZeneca","started":"2020-11-30","startedType":"actual","yearReported":2024,"enrolled":30,"enrolledBasis":"registry","outcomes":[{"endpoint":"Disease-free Survival (DFS)","primary":true,"unit":"months","arms":[{"name":"Durvalumab","n":15,"value":3.9,"note":"95% CI 3.515 to NA; Figures from the ClinicalTrials.gov results section (first posted 2024-06-25), not from a publication"},{"name":"Placebo","n":15,"value":2,"note":"95% CI 1.643 to 3.910"}],"source":"https://clinicaltrials.gov/study/NCT04642469?tab=results"}]},"route":"/trials/mermaid-2/","neighbours":{"trial":[{"id":"mermaid-1","kind":"trial","name":"MERMAID-1","route":"/trials/mermaid-1/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}]}}